Alphanavi Pharma Inc

AlphaNavi Pharma is developing a potent and selective voltage-gated sodium channel Nav1.7, Nav1.8 and Nav1.9 inhibitor, ANP-230, for neuropathic pain, including Nav-mutated rare pain diseases. It is has been reported that Nav1.7, Nav1.8 and Nav1.9 are mainly expressed in peripheral nervous system and gain-of function mutations of those Navs induce treatment-resistant rare pain diseases, including erythromelalgia and familial episodic limb pain. ANP-230 might be only one published clinical-stage compound which inhibits Nav1.9. In addition, due to high peripheral Nav selectivity and quite low penetration rate to blood-brain barrier, ANP-230 has less CV- and CNS-related side effects, while it still has potent analgesic efficacy. ANP-230 showed good tolerability in several Phase 1 studies in the US/UK and Japan and had proof-of mechanism signals in human pain challenge study. AlphaNavi Pharma is now conducting a Phase 1/2 study of ANP-230 for Nav1.9 mutated familial episodic limb pain in Japan. In parallel, we are seeking the opportunities of out-licensing to expand the clinical development of ANP-230 for neuropathic pain in the US, EU and China.